8-K
Staar Surgical Co (STAA)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 2, 2023
STAAR Surgical Company
(Exact Name of Registrant as Specified in Charter)
| Delaware | 0-11634 | 95-3797439 |
|---|---|---|
| (State or Other Jurisdiction<br> <br>of Incorporation) | (Commission<br> <br>File Number) | (IRS Employer<br> <br>Identification No.) |
| 25651 Atlantic Ocean Drive<br> <br>Lake Forest, California | 92630 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: 626-303-7902
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|---|---|---|
| Common | STAA | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 2, 2023, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended June 30, 2023, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 9.01 Financial Statements and Exhibits
| Exhibit<br>No. | Description |
|---|---|
| 99.1 | Press release of the Company dated August 2, 2023. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STAAR Surgical Company | ||
|---|---|---|
| August 2, 2023 | By: | /s/ Tom Frinzi |
| Thomas G. Frinzi | ||
| President and Chief Executive Officer |
EX-99.1
Exhibit 99.1
STAAR Surgical Reports Second Quarter 2023 Results
Record ICL Sales of $93.1Million Up 19% Y/Y
LAKE FOREST, CA, August 2, 2023 — STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023.
Second Quarter 2023Overview
| • | Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products<br> |
|---|---|
| • | Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency |
| --- | --- |
| • | ICL Units Up 21% Y/Y |
| --- | --- |
| • | Gross Margin at 76.6% vs. 78.8% in the Prior Year Quarter |
| --- | --- |
| • | Net Income of $0.12 per Share vs. $0.26 per Share in the Prior Year Quarter |
| --- | --- |
| • | Cash, Cash Equivalents and Investments Available for Sale Ended the Quarter at $209.5 Million<br> |
| --- | --- |
| • | Accounting adjustments related to Other Products resulted in Adjusted Net Sales of $93.0 Million; Adjusted<br>Gross Profit Margin of 79.8% and Adjusted Net Income for ICL of $0.19 per Share. |
| --- | --- |
“Record second quarter global ICL sales of $93.1 million up 19%, were driven by strength in our APAC region which generated 26% ICL sales growth,” said Tom Frinzi, President and CEO of STAAR Surgical. “The peak implant season for our proprietary family of EVO ICL lenses in China, the largest market for refractive procedures in the world, had a strong start in June, during which I had the pleasure of working with our team on the ground for several days. In APAC geographies, EVO has a strong market position and a long runway for growth. In the nascent U.S. market, ICL growth exceeded industry trends and although below our expectations we remain confident this market will achieve the growth levels we have seen in our other target markets. In the U.S. ICL sales were up 10% in the second quarter as compared to refractive industry procedures which were down 15%.^1^ We have taken a number of steps and implemented initiatives that we expect will accelerate EVO adoption in the U.S. as we exit 2023 and beyond.”
Mr. Frinzi continued, “Given increased conservatism related to the global environment, and a revised near-term outlook for U.S. growth, we are updating our fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million. At the mid-point of the range, our outlook represents approximately 20% growth over fiscal 2022 ICL sales of approximately $270 million. The actions we are taking, and the feedback from our customers and their happy EVO patients, make us confident that we will continue to build upon our position as the fastest growing company within the refractive industry in our target markets.”
Financial Overview – Q2 2023
During the quarter, the Company recorded various accounting adjustments related to its Other Products, specifically its non-core Cataract IOL business which the Company had previously announced it will no longer support after fiscal 2023. These adjustments included a $0.7 million reduction in net sales related to sales return reserve of certain IOL products; $2.8 million in inventory reserves related to IOL products; $0.2 million impairment of intangible assets; and a $0.4 million tax benefit; in each case related to Other Products. Please refer to the reconciliation of GAAP to Non-GAAP in the Financial Metrics Excluding Other Product Cataract IOL Adjustments table for the impact on various financial measures.
Net sales were $92.3 million for the second quarter of 2023, up 14% compared to $81.1 million reported in the prior year quarter. The sales increase in the second quarter was driven by ICL sales growth of 19% and ICL unit growth of 21%, both as compared to the prior year period. In addition to the markets noted above, ICL units in EMEA markets were down 23% (with European markets up 6%, Latin America markets up 19%, and Middle East markets down 67%), primarily due to an inability to ship ICLs into one country as a result of changes in product labeling requirements. Other Product sales for the second quarter of 2023 were ($0.8) million compared to $3.2 million in the prior year quarter, reflecting a $2.5 million reduction in Cataract IOL sales and a $1.5 million decrease in other product sales due to decreased sales of cataract injector parts and sales return reserves related to Cataract IOLs. Adjusted Net Sales which reflects an adjustment for the $0.7 million reduction related to sales return reserve for Other Products was $93.0 million for the second quarter.
Gross profit margin for the second quarter of 2023 was 76.6% compared to the prior year quarter of 78.8%. Factors impacting gross margin in the second quarter of 2023, as compared to the prior year quarter include inventory reserves related to the Other Products Cataract IOL business. Adjusted Gross Profit Margin which reflects an adjustment for the $2.8 million in inventory reserves related to Other Products was 79.8% for the second quarter.
Operating expenses for the second quarter of 2023 were $62.1 million compared to the prior year quarter of $46.9 million. General and administrative expenses were $18.1 million compared to the prior year quarter of $14.0 million. The increase in general and administrative expenses was due to increased compensation related expenses, outside services and facilities costs. Selling and marketing expenses were $32.3 million compared to the prior year quarter of $24.2 million. The increase in selling and marketing expenses is due to increased advertising and promotional activities, compensation related expenses, trade shows and sales meetings. Research and development expenses were $11.8 million compared to the prior year quarter of $8.6 million. The increase in research and development expenses is due to increased compensation related expenses and clinical trial expenses related to U.S. post-approval studies. Adjusted Operating expenses which reflects an adjustment for the $0.2 million impairment of intangible assets related to Other Products was $62.0 million.
Net income for the second quarter of 2023 was $6.1 million or $0.12 per diluted share compared with net income of $13.0 million or $0.26 per diluted share for the prior year quarter. The year over year decrease in net income is attributable to higher operating expenses partially offset by higher gross profit and interest income. Adjusted Net Income for the second quarter of 2023 was $19.7 million or $0.40 per diluted share compared to $20.7 million or $0.42 per diluted share for the prior year quarter. This includes $3.3 million reduction in net income or $(0.07) per diluted share resulting in Adjusted Net Income for ICL of $9.4 million or $0.19 per diluted share for the second quarter.
Cash, cash equivalents, and investments available for sale at June 30, 2023, totaled $209.5 million, compared to $225.5 million at end of the fourth quarter of 2022.
| ^1^ | Refractive Surgery Council, RSC Quarterly Statistical Program, Q2 2023 Report, U.S. refractive procedure<br>volumes down 14.9% Y/Y in Q2 2023 and down 9.1% sequentially from Q1 2023. |
|---|
Conference Call
The Company will host a conference call and webcast today, Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 99981426), please dial 888-259-6580 for domestic participants and 206-962-3782 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call (Replay Code 981426) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 877-674-7070 for domestic callers and 416-764-8692 for international callers. An archived webcast will also be available at www.staar.com.
Use of Non-GAAP Financial Measures
This press release includes supplemental Non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
“Adjusted Net Income” and “Adjusted Net Income for ICL” exclude the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): Cataract IOL sales return reserve, Cataract IOL inventory reserve, Cataract IOL intangible impairment, income tax benefit on Cataract IOL Adjusted Net Income also excludes gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments (if any). Management believes that “Adjusted Net Income” and “Adjusted Net Income for ICL” are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.
Management has excluded accounting adjustments related to exiting the Company’s non-core Cataract IOL business. These accounting adjustments include sales returns reserve, excess inventory reserves, an impairment charge related to cataract IOLs and the associated tax benefit of these adjustments. The Company has excluded these items in order to focus on its core ICL business as the Company will continue tapering the manufacturing of cataract IOLs, though it will continue to support these products through the end of 2023, as supplies permit. Management believes that disclosing Adjusted Net Income and Adjusted Net Income for ICL excluding these accounting adjustments is useful to investors in gauging the performance of its core ICL business.
For the reasons referenced above in connection with calculating Adjusted Net Income and Adjusted Net Income for ICL, management also supplements the Company’s GAAP consolidated financial statements and GAAP financial measures with other Non-GAAP financial measures, comprising of Adjusted Net Sales, Adjusted Cost of Sales, Adjusted Gross Profit Margin, Adjusted Operating Expenses, Adjusted Income Tax Provision, which in each case exclude the impact of any accounting adjustments related to the exiting of the Company’s non-core Cataract IOL business. The Company believes that these Non-GAAP financial measures provide additional insight into the ongoing financial results of its business which investors find useful to gauge the performance of its core ICL business.
Management has also excluded from the calculation of Adjusted Net Income gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized. In calculating Adjusted Net Income, STAAR excludes stock-based compensation expenses and valuation allowance adjustments (if any) because they are non-cash expenses and because of the considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.
The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s
results when reported in U.S. dollars. In order to compare the Company’s performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the “constant currency” rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this Non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the Non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company’s performance without the external effect of changes in relative currency values. The table provided in this press release shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting Non-GAAP measure expressed in constant currency.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer^®^ Lens or “ICL,” which includes the EVO ICL^™^ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the quarter and fiscal year 2023. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
| CONTACT: | Investors and Media<br> <br>Brian Moore<br><br><br>Vice President, Investor, Media Relations and Corporate Development<br><br><br>(626) 303-7902, Ext. 3023<br><br><br>bmoore@staar.com |
|---|
Consolidated Balance Sheets
(in 000’s)
Unaudited
| ASSETS | June 30, 2023 | December 30,2022 | ||||
|---|---|---|---|---|---|---|
| Current assets: | ||||||
| Cash and cash equivalents | $ | 94,695 | $ | 86,480 | ||
| Investments available for sale | 97,312 | 125,159 | ||||
| Accounts receivable trade, net | 94,442 | 62,447 | ||||
| Inventories, net | 25,482 | 24,161 | ||||
| Prepayments, deposits, and other current assets | 16,072 | 13,476 | ||||
| Total current assets | 328,003 | 311,723 | ||||
| Investments available for sale | 17,525 | 13,902 | ||||
| Property, plant, and equipment, net | 55,924 | 50,921 | ||||
| Finance lease<br>right-of-use assets, net | 257 | 342 | ||||
| Operating lease<br>right-of-use assets, net | 31,530 | 30,270 | ||||
| Intangible assets, net | — | 173 | ||||
| Goodwill | 1,786 | 1,786 | ||||
| Deferred income taxes | 4,672 | 4,824 | ||||
| Other assets | 954 | 957 | ||||
| Total assets | $ | 440,651 | $ | 414,898 | ||
| LIABILITIES ANDSTOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 11,441 | $ | 11,576 | ||
| Obligations under finance leases | 162 | 169 | ||||
| Obligations under operating leases | 4,013 | 3,524 | ||||
| Allowance for sales returns | 6,653 | 5,706 | ||||
| Other current liabilities | 31,925 | 30,741 | ||||
| Total current liabilities | 54,194 | 51,716 | ||||
| Obligations under finance leases | 125 | 210 | ||||
| Obligations under operating leases | 28,189 | 27,136 | ||||
| Deferred income taxes | 1,295 | 1,489 | ||||
| Asset retirement obligations | 101 | 220 | ||||
| Pension liability | 3,050 | 1,935 | ||||
| Total liabilities | 86,954 | 82,706 | ||||
| Stockholders’ equity: | ||||||
| Common stock | 485 | 482 | ||||
| Additional paid-in capital | 419,594 | 404,189 | ||||
| Accumulated other comprehensive income (loss) | (2,521 | ) | 156 | |||
| Accumulated deficit | (63,861 | ) | (72,635 | ) | ||
| Total stockholders’ equity | 353,697 | 332,192 | ||||
| Total liabilities and stockholders’ equity | $ | 440,651 | $ | 414,898 |
Consolidated Statements of Income
(In 000’s except for per share data)
Unaudited
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % of<br><br><br>Sales | June 30, 2023 | % of<br><br><br>Sales | July 1, 2022 | Fav (Unfav) | % of<br><br><br>Sales | June 30, 2023 | % of<br><br><br>Sales | July 1, 2022 | Fav (Unfav) | ||||||||||||||||||||||||||
| Amount | % | Amount | % | ||||||||||||||||||||||||||||||||
| Net sales | 100.0 | % | $ | 92,306 | 100.0 | % | $ | 81,101 | $ | 11,205 | 13.8 | % | 100.0 | % | $ | 165,834 | 100.0 | % | $ | 144,301 | $ | 21,533 | 14.9 | % | |||||||||||
| Cost of sales | 23.4 | % | 21,580 | 21.2 | % | 17,229 | (4,351 | ) | -25.3 | % | 22.6 | % | 37,546 | 21.6 | % | 31,165 | (6,381 | ) | -20.5 | % | |||||||||||||||
| Gross profit | 76.6 | % | 70,726 | 78.8 | % | 63,872 | 6,854 | 10.7 | % | 77.4 | % | 128,288 | 78.4 | % | 113,136 | 15,152 | 13.4 | % | |||||||||||||||||
| Selling, general and administrative expenses: | |||||||||||||||||||||||||||||||||||
| General and administrative | 19.6 | % | 18,097 | 17.2 | % | 13,983 | (4,114 | ) | -29.4 | % | 21.8 | % | 36,195 | 18.0 | % | 25,923 | (10,272 | ) | -39.6 | % | |||||||||||||||
| Selling and marketing | 35.0 | % | 32,277 | 29.9 | % | 24,233 | (8,044 | ) | -33.2 | % | 35.4 | % | 58,631 | 28.8 | % | 41,503 | (17,128 | ) | -41.3 | % | |||||||||||||||
| Research and development | 12.7 | % | 11,755 | 10.7 | % | 8,636 | (3,119 | ) | -36.1 | % | 13.3 | % | 22,065 | 11.4 | % | 16,577 | (5,488 | ) | -33.1 | % | |||||||||||||||
| Total selling, general, and administrative expenses | 67.3 | % | 62,129 | 57.8 | % | 46,852 | (15,277 | ) | -32.6 | % | 70.5 | % | 116,891 | 58.2 | % | 84,003 | (32,888 | ) | -39.2 | % | |||||||||||||||
| Operating income | 9.3 | % | 8,597 | 21.0 | % | 17,020 | (8,423 | ) | -49.5 | % | 6.9 | % | 11,397 | 20.2 | % | 29,133 | (17,736 | ) | -60.9 | % | |||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||||||||||||||
| Interest income, net | 1.9 | % | 1,775 | 0.1 | % | 43 | 1,732 | 4027.9 | % | 2.2 | % | 3,597 | 0.0 | % | 37 | 3,560 | 9621.6 | % | |||||||||||||||||
| Loss on foreign currency transactions | -2.0 | % | (1,890 | ) | -2.3 | % | (1,860 | ) | (30 | ) | -1.6 | % | -1.1 | % | (1,856 | ) | -1.9 | % | (2,775 | ) | 919 | 33.1 | % | ||||||||||||
| Royalty income | 0.0 | % | 0 | 0.2 | % | 177 | (177 | ) | -100.0 | % | 0.0 | % | 0 | 0.3 | % | 450 | (450 | ) | -100.0 | % | |||||||||||||||
| Other income, net | 0.0 | % | 10 | 0.1 | % | 89 | (79 | ) | -88.8 | % | 0.0 | % | 73 | 0.1 | % | 151 | (78 | ) | -51.7 | % | |||||||||||||||
| Total other income (expense), net | -0.1 | % | (105 | ) | -1.9 | % | (1,551 | ) | 1,446 | 93.2 | % | 1.1 | % | 1,814 | -1.5 | % | (2,137 | ) | 3,951 | 184.9 | % | ||||||||||||||
| Income before provision for income taxes | 9.2 | % | 8,492 | 19.1 | % | 15,469 | (6,977 | ) | -45.1 | % | 8.0 | % | 13,211 | 18.7 | % | 26,996 | (13,785 | ) | -51.1 | % | |||||||||||||||
| Provision for income taxes | 2.6 | % | 2,428 | 3.0 | % | 2,431 | 3 | 0.1 | % | 2.7 | % | 4,437 | 3.0 | % | 4,356 | (81 | ) | -1.9 | % | ||||||||||||||||
| Net income | 6.6 | % | $ | 6,064 | 16.1 | % | $ | 13,038 | $ | (6,974 | ) | -53.5 | % | 5.3 | % | $ | 8,774 | 15.7 | % | $ | 22,640 | $ | (13,866 | ) | -61.2 | % | |||||||||
| Net income per share - basic | $ | 0.13 | $ | 0.27 | $ | 0.18 | $ | 0.47 | |||||||||||||||||||||||||||
| Net income per share - diluted | $ | 0.12 | $ | 0.26 | $ | 0.18 | $ | 0.46 | |||||||||||||||||||||||||||
| Weighted average shares outstanding - basic | 48,418 | 47,889 | 48,333 | 47,822 | |||||||||||||||||||||||||||||||
| Weighted average shares outstanding - diluted | 49,516 | 49,223 | 49,524 | 49,264 |
Consolidated Statements of Cash Flows
(in 000’s)
Unaudited
| Three Months Ended | Six Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 30, 2023 | July 1, 2022 | June 30, 2023 | July 1, 2022 | |||||||||
| Cash flows from operating activities: | ||||||||||||
| Net income | $ | 6,064 | $ | 13,038 | $ | 8,774 | $ | 22,640 | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating<br>activities: | ||||||||||||
| Depreciation of property and equipment | 1,285 | 1,030 | 2,398 | 2,024 | ||||||||
| Amortization of long-lived intangibles | 164 | 7 | 171 | 15 | ||||||||
| Accretion/Amortization of investments available for sale | (841 | ) | — | (1,824 | ) | — | ||||||
| Deferred income taxes | 18 | — | 75 | — | ||||||||
| Change in net pension liability | (614 | ) | 11 | (627 | ) | 52 | ||||||
| Stock-based compensation expense | 8,423 | 5,754 | 14,488 | 9,648 | ||||||||
| Change in asset retirement obligation | (107 | ) | — | (107 | ) | — | ||||||
| Loss on disposal of property and equipment | 24 | — | 24 | — | ||||||||
| Provision for sales returns and bad debts | 1,381 | 994 | 1,004 | 800 | ||||||||
| Inventory provision | 3,016 | 994 | 3,630 | 1,428 | ||||||||
| Changes in working capital: | ||||||||||||
| Accounts receivable | (31,234 | ) | (16,210 | ) | (32,344 | ) | (20,137 | ) | ||||
| Inventories | (462 | ) | (342 | ) | (4,382 | ) | (1,825 | ) | ||||
| Prepayments, deposits and other current assets | 1,584 | 2,245 | (2,665 | ) | (2,260 | ) | ||||||
| Accounts payable | 1,721 | 575 | (1,447 | ) | 3,243 | |||||||
| Other current liabilities | 3,272 | 5,150 | 1,432 | (6,992 | ) | |||||||
| Net cash provided by (used in) operating activities | (6,306 | ) | 13,246 | (11,400 | ) | 8,636 | ||||||
| Cash flows from investing activities: | ||||||||||||
| Acquisition of property and equipment | (3,014 | ) | (5,271 | ) | (5,915 | ) | (7,810 | ) | ||||
| Purchase of investments available for sale | (15,157 | ) | — | (42,602 | ) | — | ||||||
| Proceeds from sale or maturity of investments available for sale | 28,343 | — | 68,622 | — | ||||||||
| Net cash provided by (used in) investing activities | 10,172 | (5,271 | ) | 20,105 | (7,810 | ) | ||||||
| Cash flows from financing activities: | ||||||||||||
| Repayment of finance lease obligations | (40 | ) | (27 | ) | (82 | ) | (45 | ) | ||||
| Repurchase of employee common stock for taxes withheld | (135 | ) | — | (1,984 | ) | — | ||||||
| Proceeds from vested restricted stock and exercise of stock options | 1,477 | 2,234 | 2,007 | 3,146 | ||||||||
| Net cash provided by (used in) financing activities | 1,302 | 2,207 | (59 | ) | 3,101 | |||||||
| Effect of exchange rate changes on cash and cash equivalents | (441 | ) | (759 | ) | (431 | ) | (1,143 | ) | ||||
| Increase in cash and cash equivalents | 4,727 | 9,423 | 8,215 | 2,784 | ||||||||
| Cash and cash equivalents, at beginning of the period | 89,968 | 193,067 | 86,480 | 199,706 | ||||||||
| Cash and cash equivalents, at end of the period | $ | 94,695 | $ | 202,490 | $ | 94,695 | $ | 202,490 |
Reconciliation of Non-GAAP Financial Measure
Financial Metrics Excluding Other Product Cataract IOL Adjustmenrts
(in 000’s)
Unaudited
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % ofSales | June 30,2023 | % ofSales | July 1,2022 | Fav (Unfav) | % ofSales | June 30,2023 | % ofSales | July 1,2022 | Fav (Unfav) | ||||||||||||||||||||||||
| Amount | % | Amount | % | ||||||||||||||||||||||||||||||
| Net sales: | |||||||||||||||||||||||||||||||||
| Net sales, GAAP | 100.0 | % | $ | 92,306 | 100.0 | % | $ | 81,101 | $ | 11,205 | 13.8 | % | 100.0 | % | $ | 165,834 | 100.0 | % | $ | 144,301 | $ | 21,533 | 14.9 | % | |||||||||
| Add: Cataract IOL sales return reserve | 742 | — | 742 | 742 | — | 742 | |||||||||||||||||||||||||||
| Adjusted Net sales, Non-GAAP | 100.0 | % | $ | 93,048 | 100.0 | % | $ | 81,101 | $ | 11,947 | 14.7 | % | 100.0 | % | $ | 166,576 | 100.0 | % | $ | 144,301 | $ | 22,275 | 15.4 | % | |||||||||
| Cost of sales: | |||||||||||||||||||||||||||||||||
| Cost of sales, GAAP | 23.4 | % | $ | 21,580 | 21.2 | % | $ | 17,229 | $ | (4,351 | ) | -25.3 | % | 22.6 | % | $ | 37,546 | 21.6 | % | $ | 31,165 | $ | (6,381 | ) | -20.5 | % | |||||||
| Less: Cataract IOL inventory reserve | (2,800 | ) | — | 2,800 | (2,800 | ) | — | 2,800 | |||||||||||||||||||||||||
| Adjusted Cost of sales, Non-GAAP | 20.2 | % | $ | 18,780 | 21.2 | % | $ | 17,229 | $ | (1,551 | ) | -9.0 | % | 20.9 | % | $ | 34,746 | 21.6 | % | $ | 31,165 | $ | (3,581 | ) | -11.5 | % | |||||||
| Gross Profit Margin: | |||||||||||||||||||||||||||||||||
| Gross Profit Margin, GAAP | 76.6 | % | $ | 70,726 | 78.8 | % | $ | 63,872 | $ | 6,854 | 10.7 | % | 77.4 | % | $ | 128,288 | 78.4 | % | $ | 113,136 | $ | 15,152 | 13.4 | % | |||||||||
| Add: Cataract IOL sales return reserve | 742 | — | 742 | 742 | — | 742 | |||||||||||||||||||||||||||
| Add: Cataract IOL inventory reserve | 2,800 | — | 2,800 | 2,800 | — | 2,800 | |||||||||||||||||||||||||||
| Adjusted Gross Profit Margin, Non-GAAP | 79.8 | % | $ | 74,268 | 78.8 | % | $ | 63,872 | $ | 10,396 | 16.3 | % | 79.1 | % | $ | 131,830 | 78.4 | % | $ | 113,136 | $ | 18,694 | 16.5 | % | |||||||||
| Operating expenses: | |||||||||||||||||||||||||||||||||
| Operating expenses, GAAP | 67.3 | % | $ | 62,129 | 57.8 | % | $ | 46,852 | $ | (15,277 | ) | -32.6 | % | 70.5 | % | $ | 116,891 | 58.2 | % | $ | 84,003 | $ | (32,888 | ) | -39.2 | % | |||||||
| Less: Cataract IOL intangible impairment | (154 | ) | — | 154 | (154 | ) | — | 154 | |||||||||||||||||||||||||
| Adjusted Operating expenses, Non-GAAP | 66.6 | % | $ | 61,975 | 57.8 | % | $ | 46,852 | $ | (15,123 | ) | -32.3 | % | 70.1 | % | $ | 116,737 | 58.2 | % | $ | 84,003 | $ | (32,734 | ) | -39.0 | % | |||||||
| Provision for income taxes: | |||||||||||||||||||||||||||||||||
| Provision for income taxes, GAAP | 2.6 | % | $ | 2,428 | 3.0 | % | $ | 2,431 | $ | 3 | 0.1 | % | 2.7 | % | $ | 4,437 | 3.0 | % | $ | 4,356 | $ | (81 | ) | -1.9 | % | ||||||||
| Add: Income tax benefit on Cataract IOL | 405 | — | (405 | ) | 405 | — | (405 | ) | |||||||||||||||||||||||||
| Adjusted Provision for income taxes, Non-GAAP | 3.0 | % | $ | 2,833 | 3.0 | % | $ | 2,431 | $ | (402 | ) | -16.5 | % | 2.9 | % | $ | 4,842 | 3.0 | % | $ | 4,356 | $ | (486 | ) | -11.2 | % |
Reconciliation of Non-GAAP Financial Measure
Adjusted Net Income and Net Income Per Share
(in000’s)
Unaudited
| Three Months Ended | Six Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| June 30, 2023 | July 1, 2022 | June 30, 2023 | July 1, 2022 | |||||||
| Net income (as reported) | $ | 6,064 | $ | 13,038 | $ | 8,774 | $ | 22,640 | ||
| Less | ||||||||||
| Cataract IOL sales return reserve | 742 | — | 742 | — | ||||||
| Cataract IOL inventory reserve | 2,800 | — | 2,800 | — | ||||||
| Cataract IOL intangible impairment | 154 | — | 154 | — | ||||||
| Income tax benefit on Cataract IOL | (405 | ) | — | (405 | ) | — | ||||
| Adjusted net income for ICL | **** | 9,355 | **** | **** | 13,038 | **** | 12,065 | **** | **** | 22,640 |
| Less: | ||||||||||
| Foreign currency impact | 1,890 | 1,860 | 1,856 | 2,775 | ||||||
| Stock-based compensation expense | 8,423 | 5,754 | 14,488 | 9,648 | ||||||
| Net income (adjusted) | $ | 19,668 | **** | $ | 20,652 | $ | 28,409 | **** | $ | 35,063 |
| Net income per share, basic (as reported) | $ | 0.13 | $ | 0.27 | $ | 0.18 | $ | 0.47 | ||
| Cataract IOL sales return reserve | 0.02 | — | 0.02 | — | ||||||
| Cataract IOL inventory reserve | 0.06 | — | 0.06 | — | ||||||
| Cataract IOL intangible impairment | — | — | — | — | ||||||
| Income tax benefit on Cataract IOL | (0.01 | ) | — | (0.01 | ) | — | ||||
| Adjusted net income for ICL per share, basic | **** | 0.19 | **** | **** | 0.27 | **** | 0.25 | **** | **** | 0.47 |
| Foreign currency impact | 0.04 | 0.04 | 0.04 | 0.06 | ||||||
| Stock-based compensation expense | 0.17 | 0.12 | 0.30 | 0.20 | ||||||
| Net income per share, basic (adjusted) | $ | 0.41 | **** | $ | 0.43 | $ | 0.59 | **** | $ | 0.73 |
| Net income per share, diluted (as reported) | $ | 0.12 | $ | 0.26 | $ | 0.18 | $ | 0.46 | ||
| Cataract IOL sales return reserve | 0.01 | — | 0.01 | — | ||||||
| Cataract IOL inventory reserve | 0.06 | — | 0.06 | — | ||||||
| Cataract IOL intangible impairment | — | — | — | — | ||||||
| Income tax benefit on Cataract IOL | (0.01 | ) | — | (0.01 | ) | — | ||||
| Adjusted net income for ICL per share, diluted | **** | 0.19 | **** | **** | 0.26 | **** | 0.24 | **** | **** | 0.46 |
| Foreign currency impact | 0.04 | 0.04 | 0.04 | 0.06 | ||||||
| Stock-based compensation expense | 0.17 | 0.12 | 0.29 | 0.19 | ||||||
| Net income per share, diluted (adjusted) | $ | 0.40 | **** | $ | 0.42 | $ | 0.57 | **** | $ | 0.71 |
| Weighted average shares outstanding—Basic | 48,418 | 47,889 | 48,333 | 47,822 | ||||||
| Weighted average shares outstanding—Diluted | 49,516 | 49,223 | 49,524 | 49,264 |
Note: Net income per share (adjusted), basic and diluted, may not add due to rounding
STAAR Surgical Company
Reconciliation of Non-GAAP Financial Measure
Constant Currency Sales
(in 000’s)
Unaudited
| Three Months Ended | July 1, 2022 | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | June 30, 2023 | Effect of<br>Currency | Constant<br>Currency | Change | % Change | Change | % Change | ||||||||||||||||
| ICL | $ | 93,112 | $ | 390 | $ | 93,502 | $ | 77,922 | 15,190 | 19.5 | % | 15,580 | 20.0 | % | |||||||||
| Cataract IOL | 40 | 2 | 42 | 2,547 | (2,507 | ) | -98.4 | % | (2,505 | ) | -98.4 | % | |||||||||||
| Other | (846 | ) | (15 | ) | (861 | ) | 632 | (1,478 | ) | -233.9 | % | (1,493 | ) | -236.2 | % | ||||||||
| Other Products | (806 | ) | (13 | ) | (819 | ) | 3,179 | (3,985 | ) | -125.4 | % | (3,998 | ) | -125.8 | % | ||||||||
| Total Sales | $ | 92,306 | $ | 377 | $ | 92,683 | $ | 81,101 | 11,205 | 13.8 | % | 11,582 | 14.3 | % | |||||||||
| Six Months Ended | July 1, 2022 | ||||||||||||||||||||||
| Sales | June 30, 2023 | Effect of<br>Currency | Constant<br>Currency | Change | % Change | Change | % Change | ||||||||||||||||
| ICL | $ | 163,737 | $ | 2,116 | $ | 165,853 | $ | 136,597 | 27,140 | 19.9 | % | 29,256 | 21.4 | % | |||||||||
| Cataract IOL | 1,516 | 159 | 1,675 | 5,449 | (3,933 | ) | -72.2 | % | (3,774 | ) | -69.3 | % | |||||||||||
| Other | 581 | 112 | 693 | 2,255 | (1,674 | ) | -74.2 | % | (1,562 | ) | -69.3 | % | |||||||||||
| Other Products | 2,097 | 271 | 2,368 | 7,704 | (5,607 | ) | -72.8 | % | (5,336 | ) | -69.3 | % | |||||||||||
| Total Sales | $ | 165,834 | $ | 2,387 | $ | 168,221 | $ | 144,301 | 21,533 | 14.9 | % | 23,920 | 16.6 | % |
All values are in US Dollars.